Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 3/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 17/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 17/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3312091 | 0.89 | TYK2 (0.46) | TYK2STAT3CSNK2A2CSNK2A1 | |
| SCHEMBL2359655 | 0.86 | TYK2 (0.46) | TYK2STAT3CSNK2A2CSNK2A1 | |
| SCHEMBL3312329 | 0.83 | TYK2 (0.58) | TYK2STAT3CSNK2A2CSNK2A1 | |
| SCHEMBL17849715 | 0.82 | TYK2 (0.46) | TYK2STAT3CSNK2A2CSNK2A1 | |
| SCHEMBL2306697 | 0.81 | CSNK2A2 (0.49) | TYK2STAT3CSNK2A2CSNK2A1 | |
| SCHEMBL3313278 | 0.81 | TYK2 (0.53) | TYK2STAT3CSNK2A2CSNK2A1 | |
| SCHEMBL2358151 | 0.81 | TYK2 (0.44) | TYK2STAT3CSNK2A2CSNK2A1 | |
| SCHEMBL3313808 | 0.80 | TYK2 (0.47) | TYK2STAT3CSNK2A2CSNK2A1 | |
| SCHEMBL3311217 | 0.80 | TYK2 (0.59) | TYK2STAT3CSNK2A2CSNK2A1 | |
| SCHEMBL2358888 | 0.80 | TYK2 (0.47) | TYK2STAT3CSNK2A2CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371328-B2 | Imidazopyridazinecarbonitriles useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-21 | — | — | US | disclosed |
| US-20120283241-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283241-A1 | IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | MAP3K5, MAP3K15, MAP4K2 | TYK2 393/4885STAT3 764/4885CSNK2A2 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.